CJC-1295 (No DAC) for Bone Health
Research, mechanism, dosing, and effectiveness of CJC-1295 (No DAC) for bone health.
Quick Answer
CJC-1295 supports bone density through GH elevation.
Evidence Level
Human Trials
Typical Dose
100-300 mcg daily
Results Timeline
Bone benefits over 6-12 months
FDA Status
Research Only
How CJC-1295 (No DAC) Works for Bone Health
Growth hormone promotes osteoblast activity.
About Bone Health
Support for bone density and prevention of osteoporosis.
Research Evidence
Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg.
Dosing for Bone Health
Recommended Dose
100-300 mcg daily
Frequency
Daily (no DAC) or 1-2x weekly (with DAC)
Administration
Subcutaneous injection
Duration
8-12 weeks
Note: No-DAC version requires daily dosing. DAC version has longer half-life. Often stacked with GHRP like Ipamorelin.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Generally well-tolerated
- •Injection site reactions
- •Facial flushing
- •Headache
- •Water retention
- •Dizziness
Frequently Asked Questions
Does CJC-1295 (No DAC) help with bone health?
CJC-1295 supports bone density through GH elevation.
How does CJC-1295 (No DAC) work for bone health?
Growth hormone promotes osteoblast activity....
What dose of CJC-1295 (No DAC) should I use for bone health?
100-300 mcg daily
How long until I see results?
Bone benefits over 6-12 months
Other Peptides for Bone Health
These peptides are also researched for bone health.
Ipamorelin
Clinical TrialsA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
GHRP-6
Clinical TrialsOne of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.
GHRP-2
Clinical TrialsA synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.
MK-677
Clinical TrialsAn orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.